Development of Unsymmetrical Dyads As Potent Noncarbohydrate-Based Inhibitors against Human β-N-Acetyl-d-hexosaminidase
摘要:
Human beta-N-acetyl-D-hexosaminidase has gained much attention due to its roles in several pathological processes and been considered as potential targets for disease therapy. A novel and efficient skeleton, which was an unsymmetrical dyad containing naphthalimide and methoxyphenyl moieties with an alkylamine spacer linkage as a noncarbohydrate-based inhibitor, was synthesized, and the activities were valuated against human beta-N-acetyl-D-hexosaminidase. The most potent inhibitor exhibits high inhibitory activity with K-i values of 0.63 mu M. The straightforward synthetic manner of these unsymmetrical dyads and understanding of the binding model cold be advantageous for further structure optimization and development of new therapeutic agents for Hex-related diseases.
An optical filter containing at least one naphtholactam derivative represented by general formula (I), wherein X is oxygen or sulfur; R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, and Y are each hydrogen, halogen, nitro, cyano, aldehyde, carboxyl, hydroxyl, —NRR′, organosilyl, optionally substituted C1-C30 alkyl, optionally substituted C6-C30 aryl, or optionally substituted C7-C30 arylalkyl; and R and R′ are each hydrogen, optionally substituted C1-C30 alkyl, or optionally substituted C6-C30 aryl.
Human beta-N-acetyl-D-hexosaminidase has gained much attention due to its roles in several pathological processes and been considered as potential targets for disease therapy. A novel and efficient skeleton, which was an unsymmetrical dyad containing naphthalimide and methoxyphenyl moieties with an alkylamine spacer linkage as a noncarbohydrate-based inhibitor, was synthesized, and the activities were valuated against human beta-N-acetyl-D-hexosaminidase. The most potent inhibitor exhibits high inhibitory activity with K-i values of 0.63 mu M. The straightforward synthetic manner of these unsymmetrical dyads and understanding of the binding model cold be advantageous for further structure optimization and development of new therapeutic agents for Hex-related diseases.